Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

Sminu Bose · SciRah

Researcher profile · Semantic Scholar

Sminu Bose

Share profile

Sminu Bose — researcher profile on SciRah

h-index: 7
Works: 26
Citations: 1,492

Most-cited papers

Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B-cells
A. Le, A. Lane, M. Hamaker, Sminu Bose +13 more
2012Cell Metabolism1,086 citations Open access
Semantic Scholar
Glucose Metabolism in Cancer: The Warburg Effect and Beyond
Sminu Bose, Cissy Zhang, A. Le
2021Advances in Experimental Medicine and Biology175 citations Open access
Semantic Scholar
Glucose Metabolism in Cancer.
Sminu Bose, A. Le
2018Advances in Experimental Medicine and Biology101 citations
Semantic Scholar
Therapeutic advances in leiomyosarcoma
K. Lacuna, Sminu Bose, M. Ingham, Gary Schwartz
2023Frontiers in Oncology48 citations Open access
Semantic Scholar
Phase II Study of Olaparib and Temozolomide for Advanced Uterine Leiomyosarcoma (NCI Protocol 10250)
M. Ingham, Jacob B. Allred, Li Chen, Biswajit Das +18 more
2023Journal of Clinical Oncology38 citations Open access
Semantic Scholar
Novel Therapeutics in the Treatment of Uterine Sarcoma.
Sminu Bose, G. Schwartz, M. Ingham
2022American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting19 citations
Semantic Scholar
Durable Clinical Activity to the AKT Inhibitor Ipatasertib in a Heavily Pretreated Patient With an AKT1 E17K Mutant Metastatic Breast Cancer.
Sminu Bose, K. Kalinsky
2020Clinical Breast Cancer7 citations
Semantic Scholar
Single-Cell Profiling of Sarcomas from Archival Tissue Reveals Programs Associated with Resistance to Immune Checkpoint Blockade
Karan D. Luthria, Parin Shah, Blake Caldwell, Johannes C. Melms +11 more
2024Clinical Cancer Research6 citations Open access
Semantic Scholar
A phase II study, with a safety lead-in, to evaluate ATX-101, a peptide drug targeting PCNA, in advanced dedifferentiated liposarcoma and leiomyosarcoma.
Sminu Bose, M. Ingham, Shahnaz V. Singh-Kandah, Wendy Magana +1 more
2022Journal of Clinical Oncology5 citations
Semantic Scholar
A phase II trial with safety lead-in to evaluate the addition of sotigalimab, a CD40 agonistic monoclonal antibody, to standard-of-care doxorubicin for the treatment of advanced sarcoma.
Sminu Bose, Lin-Er Ge, Shing M. Lee, B. Van Tine +8 more
2023Journal of Clinical Oncology3 citations
Semantic Scholar
A Phase II Trial of Olaparib Plus Pembrolizumab in Patients with Recurrent Copy-Number High/p53-Abnormal Endometrial Cancer
Maria M. Rubinstein, Jennifer Y. Ge, Qin Zhou, A. Iasonos +21 more
2026Clinical Cancer Research2 citations Open access
Semantic Scholar
ETCTN/NCI 10330: A phase 2 study of belinostat with SGI-110 (guadecitabine) or ASTX727 (decitabine/cedazuridine) for the treatment of unresectable and metastatic conventional chondrosarcoma.
K. Lacuna, Shing M. Lee, Lin-Er Ge, M. Druta +15 more
2023Journal of Clinical Oncology2 citations
Semantic Scholar
CDK4/6 Inhibition With Anti-PD-1 Checkpoint Blockade Induces Major Response in Aggressive Classic Kaposi Sarcoma After Previous Progression on Anti-PD-1 Alone.
Sminu Bose, Tristan Lee, Shaelyn Choi, Ladan Fazlollahi +3 more
2022JCO Precision Oncology2 citations
Semantic Scholar
A phase II trial of lenvatinib plus pembrolizumab in patients (pts) with endometrial or ovarian carcinosarcoma.
Sminu Bose, Corbyn M. Nchako, Qin Zhou, A. Iasonos +16 more
2026Journal of Clinical Oncology0 citations
Semantic Scholar
A randomized, multicenter, open-label, phase 2 basket study of CYP11A1 inhibitor opevesostat in participants with selected solid tumors: study design of cohorts B and C of OMAHA-015
Antonio González Martín, V. Kaklamani, Rowan E. Miller, B. Slomovitz +12 more
2026International Journal of Gynecological Cancer0 citations
Semantic Scholar
A randomized, multicenter, open-label, phase 2 basket study of CYP11A1 inhibitor opevesostat in participants with selected solid tumors: Study design of cohorts B and C of OMAHA-015
B. Slomovitz, V. Kaklamani, Rowan E. Miller, Antonio González Martín +12 more
2026Gynecologic Oncology0 citations
Semantic Scholar
Circulating tumor DNA (ctDNA) from a phase II study of adjuvant dostarlimab with pelvic radiation in locally advanced, mismatch repair–deficient (MMR-D) endometrial cancer (D-RT study).
Gabriela Sotolongo, David N. Brown, Maria M. Rubinstein, Robin Guo +16 more
2026Journal of Clinical Oncology0 citations
Semantic Scholar
Study design of OMAHA-015: A phase 2 basket study of steroidogenesis inhibitor opevesostat in participants with selected solid tumors.
V. Kaklamani, David M. O'Malley, Rowan E. Miller, A. González-Martín +12 more
2026Journal of Clinical Oncology0 citations
Semantic Scholar
Natural history and treatment outcomes in aggressive angiomyxoma: A single institution experience.
O. Babatunde, K. Seier, R. Desir-Camille, Viswatej Avutu +17 more
2026European Journal of Cancer0 citations Open access
Semantic Scholar
Adjuvant dostarlimab with pelvic radiation (RT) in locally advanced, mismatch repair-deficient (MMR-D) endometrial cancer (EC): D-RT study
Ying L. Liu, M. Rubinstein, Robin Guo, Qin Zhou +16 more
2026Gynecologic Oncology0 citations
Semantic Scholar
A phase II trial of pembrolizumab plus olaparib for the treatment of patients with persistent/recurrent endometrial cancers.
Maria M. Rubinstein, Qin Zhou, A. Iasonos, P. Selenica +16 more
2025Journal of Clinical Oncology0 citations
Semantic Scholar
The landscape of chromosomal instability in uterine leiomyosarcoma.
Sara Moufarrij, Qin Zhou, A. Iasonos, S. Hatoum +4 more
2025Journal of Clinical Oncology0 citations Open access
Semantic Scholar
Abstract 6174: ATX-101, a peptide drug targeting PCNA, enhances the effect of gemcitabine in liposarcoma and leiomyosarcoma
Elgilda Musi, Tahir N. Sheikh, M. Ingham, Sminu Bose +1 more
2023Cancer Research0 citations
Semantic Scholar
Abstract PR006: Multi-modal single-cell profiling of sarcomas from archival tissue reveals mechanisms of resistance to immune checkpoint inhibitors
Sminu Bose, Blake Caldwell, A. Amin, Johannes C. Melms +4 more
2022Clinical Cancer Research0 citations
Semantic Scholar
Multi-modal single-cell profiling of sarcomas from archival tissue reveals mechanisms of resistance to immune checkpoint inhibitors.
Blake Caldwell, Sminu Bose, A. Amin, Somnath Tagore +5 more
2022Journal of Clinical Oncology0 citations
Semantic Scholar
Abstract 784A: Profiling pancreatic cancer metabolism and tumor microenvironment for therapy
Sminu Bose, T. Tsukamoto, B. Slusher, R. Royer +2 more
20120 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

M. Ingham×10
Invite
M. Ingham — researcher profile on SciRah
G. Schwartz×8
Invite
G. Schwartz — researcher profile on SciRah
Qin Zhou×6
Invite
Qin Zhou — researcher profile on SciRah
A. Iasonos×6
Invite
A. Iasonos — researcher profile on SciRah

×5

Invite

B. Weigelt — researcher profile on SciRah

Seth M. Cohen×5

Invite

Seth M. Cohen — researcher profile on SciRah

C. Aghajanian×5

Invite

C. Aghajanian — researcher profile on SciRah

Invite

V. Makker — researcher profile on SciRah

Invite

A. Le — researcher profile on SciRah

R. O'Cearbhaill×4

Invite

R. O'Cearbhaill — researcher profile on SciRah

Invite

W. Tew — researcher profile on SciRah

Invite

K. Lacuna — researcher profile on SciRah